NGEN
NASDAQ · Pharmaceuticals
Nervgen Pharma Corp
$2.05
-0.22 (-9.69%)
Open$2.27
Previous Close$2.27
Day High$2.27
Day Low$2.04
52W High$8.49
52W Low$3.20
Volume—
Avg Volume50.7K
Market Cap325.83M
P/E Ratio—
EPS$-0.36
SectorPharmaceuticals
Analyst Ratings
Strong Buy
8 analysts
Price Target
+509.3% upside
Current
$2.05
$2.05
Target
$12.49
$12.49
$8.17
$12.49 avg
$18.41
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 153.26M | 151.64M | 138.95M |
| Net Income | 33.69M | 27.50M | 27.23M |
| Profit Margin | 22.0% | 18.1% | 19.6% |
| EBITDA | 48.41M | 46.31M | 47.02M |
| Free Cash Flow | 29.41M | 26.14M | 25.26M |
| Rev Growth | +15.3% | +9.0% | +25.0% |
| Debt/Equity | 0.51 | 0.65 | 0.45 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $1,170.14 | +0.45% | 40.7 | 1.09T |
| JNJ | Johnson & Johnson | $269.19 | -0.10% | 30.6 | 644.12B |
| MRK | Merck & Co. Inc. | $150.91 | +0.94% | 114.0 | 361.66B |
| PFE | Pfizer Inc. | $27.93 | +0.68% | 36.4 | 157.54B |
| BMY | Bristol-Myers Squibb Co | $62.25 | -0.59% | 13.9 | 128.81B |
| ZTS | Zoetis Inc | $72.86 | +2.15% | 11.5 | 30.15B |